Ankylosing Spondylitis News reported that HSS rheumatologist Susan M. Goodman, MD, and a team of researchers are investigating how secukinumab affects bone health in patients with ankylosing spondylitis (AS).

According to the article, the study is expected to last for two years.

"It's very important to get a better understanding in a practical way of the effect of these drugs on bone metabolism. This study should really help us understand how they work," said Dr. Goodman in a press release.

Read the full article at ankylosingspondylitisnews.com.